Processing...
Clinical Trials for Prostate Cancer
Search
Search
There are 228 active trials for advanced/metastatic prostate cancer.
Click on a trial to see more information.
228 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Enrolls adults with advanced malignancies, primarily HR+/HER2− advanced breast cancer that has progressed after endocrine therapy plus a CDK4/6 inhibitor (phase II limited to ≤2 prior endocrine lines for advanced disease and no prior chemotherapy/ADC in the advanced setting), with additional phase I cohorts for CCNE1-amplified solid tumors and metastatic castration-resistant prostate cancer. Patients receive the first-in-human investigational agent GVV858 (target/mechanism not publicly specified) as monotherapy or combined with endocrine therapy—fulvestrant (and letrozole in phase I), with phase II evaluating two GVV858 dose regimens plus fulvestrant.
ClinicalTrials.gov ID: NCT07288359
TrialFetch AI summary: Enrolls adults with progressive metastatic castration-resistant prostate adenocarcinoma after at least one prior novel androgen receptor pathway inhibitor, requiring PSMA-positive disease on PSMA PET (with RECIST-measurable disease or evaluable disease with PSA ≥1 ng/mL) and no CNS metastases. Patients undergo leukapheresis and receive a single IV infusion of AB-3028, an autologous logic-gated engineered T-cell therapy designed to activate only with PSMA plus a second priming antigen to improve tumor selectivity and limit on-target/off-tumor toxicity.
ClinicalTrials.gov ID: NCT07285694
TrialFetch AI summary: Adults with advanced/metastatic adrenocortical carcinoma or metastatic castration-resistant prostate cancer (ECOG 0–1; ECOG 2 allowed if due to cancer pain), with the mCRPC cohort requiring prior androgen receptor pathway inhibitor exposure and at least one prior chemotherapy line or ineligibility/refusal, receive oral DS9051b tablet monotherapy. This dose-escalation study is primarily assessing safety/DLTs and establishing the recommended expansion dose while looking for preliminary antitumor activity; DS9051b’s target/mechanism has not been publicly specified.
ClinicalTrials.gov ID: NCT07189403
TrialFetch AI summary: Adults with advanced/unresectable or metastatic solid tumors that have progressed after, are intolerant to, or lack standard systemic options (ECOG 0–1; measurable disease; excluding prior B7-H3–targeted therapy, prior topoisomerase inhibitor ADCs, significant ILD/pneumonitis, uncontrolled infection, or active/untreated CNS metastases). Patients receive SYS6043, an IV q3-week B7-H3 (CD276)–targeted antibody–drug conjugate delivering a cytotoxic payload to B7-H3–expressing tumor cells, with expansion cohorts planned in ES-SCLC, HR+/HER2− breast cancer, mCRPC, and ovarian cancer.
ClinicalTrials.gov ID: NCT07424547
TrialFetch AI summary: Enrolls adults with relapsed/refractory, locally advanced inoperable, or metastatic solid tumors (including CRPC, NSCLC/SCLC, CRC, HNSCC, ovarian/cervical/endometrial cancers, TNBC, and esophageal SCC) who have progressed after their most recent therapy and have no suitable standard option, with ECOG 0–2 and adequate organ function (measurable disease required except in CRPC; prior Lu-177–PSMA excluded for CRPC). Patients receive 177Lu-BetaBart, a lutetium-177–labeled anti–B7-H3 (CD276) monoclonal antibody delivering beta-particle radiation as systemic radioimmunotherapy in a dose-escalation/expansion design.
ClinicalTrials.gov ID: NCT07189871
TrialFetch AI summary: Eligible patients are men with metastatic castration-resistant prostate adenocarcinoma (ECOG 0–1, PSA ≥2 ng/mL) with progression on androgen-deprivation therapy and at least one prior approved secondary hormonal therapy for CRPC, without prior/active brain metastases or significant cardiac disease. Participants receive BMS-986460 monotherapy, an investigational ligand-directed degrader that binds a prostate tumor-associated antigen and recruits an E3 ubiquitin ligase to promote ubiquitination and proteasome-mediated degradation of a target protein in tumor cells.
ClinicalTrials.gov ID: NCT06067841
TrialFetch AI summary: For men with PSMA-expressing metastatic castration-resistant prostate cancer with documented progression, at least one measurable metastatic lesion, ongoing castration (orchiectomy or ADT), and prior exposure to at least one androgen receptor pathway inhibitor. Participants receive single-agent TD001, a PSMA-targeted antibody–drug conjugate that binds PSMA and delivers an internalized exatecan (topoisomerase I inhibitor) cytotoxic payload, with dose-escalation and schedule exploration to identify a recommended dosing regimen.
ClinicalTrials.gov ID: NCT07258407
TrialFetch AI summary: Enrolls adults with metastatic castration-resistant prostate adenocarcinoma (ECOG 0–1) progressing on androgen deprivation therapy after at least one prior androgen receptor pathway inhibitor and 1–2 prior taxane chemotherapy regimens, excluding small cell/neuroendocrine histology and prior AR degrader therapy. Single-arm dose-escalation/optimization study of GSK5471713 monotherapy (reported as an investigational androgen receptor degrader) to define safety/PK and look for early PSA and radiographic responses.
ClinicalTrials.gov ID: NCT07332455
TrialFetch AI summary: Adults with ECOG 0–1 and locally advanced/metastatic solid tumors, including ER+/HER2− breast cancer, NSCLC, CRPC, and MSS colorectal cancer after prior standard therapy, receive oral IDE574 monotherapy; breast cancer cohorts require prior endocrine therapy and CDK4/6 inhibitor. ER+/HER2− breast cancer patients may receive IDE574, an investigational dual KAT6/KAT7 epigenetic inhibitor, in combination with fulvestrant.
ClinicalTrials.gov ID: NCT07540572
TrialFetch AI summary: Adults with ECOG 0–1 and measurable locally advanced/metastatic solid tumors co-expressing B7-H3 and PTK7, after progression/intolerance to prior therapy or lacking standard options, including NSCLC, ESCC, endometrial, ovarian, HNSCC, TNBC, colorectal, and CRPC. All participants receive IDE034, an investigational bispecific B7-H3/PTK7 antibody–drug conjugate with a topoisomerase I inhibitor payload, in dose-escalation and expansion cohorts.
ClinicalTrials.gov ID: NCT07503808